KLRS

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by AlloVir, Inc. (Note: The input metadata referenced "Kalaris Therapeutics, Inc.", but the filing text explicitly identifies the registrant as AlloVir, Inc.) on June 6, 2024. The report details the voting results for director elections and the ratification of the independent auditor.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events rather than a financial statement.

Material Changes and Voting Results

As of the record date (April 15, 2024), there were 114,912,515 shares of common stock outstanding and entitled to vote. Stockholders approved two proposals:

• Proposal 1 (Director Election): Stockholders elected Juan Vera, M.D., Morana Jovan-Embiricos, Ph.D., and Derek Adams, Ph.D. as Class I directors to serve until the 2027 Annual Meeting.
• Proposal 2 (Auditor Ratification): Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.

Investor Verification Checklist

• Verify the correct registrant name is AlloVir, Inc. (ALVR), not Kalaris Therapeutics, Inc.
• Confirm the tenure of the newly elected Class I directors (Juan Vera, Morana Jovan-Embiricos, Derek Adams) extends to the 2027 Annual Meeting.
• Review the Definitive Proxy Statement filed on April 23, 2024, for detailed biographies of the directors and further context on the auditor selection.
• Note the significant number of broker non-votes (approx. 23 million) on the director election, which may indicate passive institutional holdings.